Insight into the emerging role of long non-coding RNAs in BRAF inhibitor resistance in melanoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Melanoma, the deadliest skin cancer, is increasingly common globally.
• BRAF mutations are prevalent in melanoma, and targeted therapies (BRAFi) improve survival.
• Acquired resistance to BRAFi is a major clinical challenge, with underlying mechanisms under investigation.

Purpose of the Study:

• To summarize the current understanding of long noncoding RNAs (lncRNAs) in acquired resistance to BRAF inhibitors (BRAFi) in melanoma.
• To explore the dual role of lncRNAs in either restoring sensitivity or conferring resistance to BRAFi.
• To discuss the potential of lncRNAs as prognostic biomarkers for BRAFi therapy response and resistance.

Main Methods:

• Literature review and synthesis of recent research findings.
• Analysis of studies investigating lncRNA expression profiles in melanoma.
• Examination of functional studies on lncRNAs in the context of BRAFi treatment.

Main Results:

• lncRNAs are implicated in the development and progression of melanoma.
• Specific lncRNAs can either re-sensitize melanoma cells to BRAFi or promote resistance.
• lncRNA expression patterns correlate with treatment response and resistance.

Conclusions:

• lncRNAs represent a critical, yet underexplored, factor in BRAFi resistance in melanoma.
• Targeting lncRNAs may offer novel therapeutic avenues to overcome BRAFi resistance.
• lncRNAs hold promise as predictive biomarkers for patient stratification and treatment selection in melanoma.